Anti C-MET antibodies
The present disclosure relates to antibody molecules that bind specifically to C-MET and related nucleic acid molecules, vectors and host cells. Also provided are medical uses of such antibody molecules. The claimed anti C-Met antibodies of the present application have been selected by in silico engineering. Some of the antibodies have been generated and further characterized after expression in mammalian expression system.
1. An anti-C-MET antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein
(a) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO: 34), HCDR2 of MGIINPSGGSTSYAQKFQG (SEQ ID NO: 35) and HCDR3 of QEITTEFDY (SEQ ID NO: 36); and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYAQSYLH (SEQ ID NO: 57), LCDR2 of RGSTRET (SEQ ID NO: 56) and LCDR3 of QQSKESPLT (SEQ ID NO: 47);
(b) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO: 34), HCDR2 of MGIINPSGGSTSYAQKFQG (SEQ ID NO: 35) and HCDR3 of QEITTEFDY (SEQ ID NO: 36); and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYANSYLH (SEQ ID NO: 37), LCDR2 of RGSTRET (SEQ ID NO: 56) and LCDR3 of QQSKESPLT (SEQ ID NO: 47); or
(c) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO: 34), HCDR2 of MGIINPSGGSTSYAQKFQG (SEQ ID NO: 35) and HCDR3 of QEITTEFDY (SEQ ID NO: 36); and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYANSYLH (SEQ ID NO: 37), LCDR2 of RGSTRET (SEQ ID NO: 56) and LCDR3 of QQSKSEPLT (SEQ ID NO: 39).
2. The antibody or antigen-binding portion of claim 1 , wherein
(a) the VH region amino acid sequence comprises SEQ ID NO:1 and the VL region amino acid sequence comprises SEQ ID NO:2;
(b) the VH region amino acid sequence comprises SEQ ID NO:3 and the VL region amino acid sequence comprises SEQ ID NO:4; or
(c) the VH region amino acid sequence comprises SEQ ID NO:5 and the VL region amino acid sequence comprises SEQ ID NO:6.
3. The antibody or antigen-binding portion of claim 1 wherein the antibody is humanized or chimeric.
4. The antibody or antigen-binding portion of claim 1 , wherein the VH region, the VL region, or both the VH and the VL region comprise one or more human framework region amino acid sequences.
5. The antibody or antigen-binding portion of claim 1 , wherein the VH region, the VL region, or both the VH and the VL region comprise a human variable region framework scaffold amino acid sequence into which the CDRs have been inserted.
6. The antibody or antigen-binding portion of claim 1 , wherein the VH region comprises an IGHV1-46 human germline scaffold amino acid sequence into which the HCDR1, HCDR2 and HCDR3 amino acid sequences have been inserted.
7. The antibody or antigen-binding portion of claim 1 , wherein the VL region comprises an IGKV3-20 human germline scaffold amino acid sequence into which the LCDR1, LCDR2 and LCDR3 amino acid sequences have been inserted.
8. The antibody or antigen-binding portion of claim 1 , wherein the antibody or antigen-binding portion comprises an immunoglobulin constant region.
9. The antibody or antigen-binding portion of claim 8 , wherein the immunoglobulin constant region is IgG, IgE, IgM, IgD, IgA or IgY.
10. The antibody or antigen-binding portion of claim 9 , wherein the immunoglobulin constant region is IgG1, IgG2, IgG3, IgG4, IgA1 or IgA2.
11. The antibody or antigen-binding portion of claim 8 , wherein the immunoglobulin constant region is immunologically inert.
12. The antibody or antigen-binding portion of claim 8 , wherein the immunoglobulin constant region is a wild-type human IgG4 constant region, a human IgG4 constant region comprising the amino acid substitution S228P, a wild-type human IgG1 constant region, a human IgG1 constant region comprising the amino acid substitutions L234A, L235A and G237A or a wild-type human IgG2 constant region.
13. The antibody or antigen-binding portion of claim 8 , wherein the immunoglobulin constant region comprises any one of SEQ ID NOS:11-17.
14. The antibody or antigen-binding portion of claim 1 , wherein the antibody or antigen-binding portion is an Fab, an Fab′, an F(ab′)2, an Fv, an scFv, a maxibody, a minibody, a diabody, a triabody, a tetrabody, or a bis-scFv.
15. The antibody or antigen-binding portion of claim 1 , wherein the antibody or antigen-binding portion is monoclonal.
16. The antibody or antigen-binding portion of claim 1 , wherein the antibody or antigen-binding portion is tetrameric, tetravalent or multispecific.
17. The antibody or antigen-binding portion of claim 1 , wherein the antibody or antigen-binding portion is a bispecific antibody or bispecific antigen-binding portion that binds specifically to a first antigen and a second antigen, wherein the first antigen is C-MET and the second antigen is not C-MET.
18. The antibody or antigen-binding portion of claim 1 , wherein the antibody or antigen-binding portion comprises a human IgG4 constant region comprising the amino acid substitution S228P, and wherein the antibody or antigen-binding portion has
(a) a melting temperature (Tm) from about 77° C. to about 81° C.; and/or
(b) an isoelectric point (pI) greater than about pH 7.4.
19. An immunoconjugate comprising the antibody or antigen-binding portion of claim 1 linked to a therapeutic agent.
20. The immunoconjugate of claim 19 , wherein the therapeutic agent is a cytotoxin, a radioisotope, a chemotherapeutic agent, an immunomodulatory agent, a cytostatic enzyme, a cytolytic enzyme, a therapeutic nucleic acid, an anti-angiogenic agent, an anti-proliferative agent, or a pro-apoptotic agent.
21. A pharmaceutical composition comprising the antibody or antigen-binding portion of claim 1 and a pharmaceutically acceptable carrier.
22. A nucleic acid molecule encoding both the VH and the VL region amino acid sequences of the antibody or antigen-binding portion of claim 1 .
23. An expression vector comprising the nucleic acid molecule of claim 22 .
24. A method of producing an anti-C-MET antibody or an antigen-binding portion thereof, the method comprising:
culturing a recombinant host cell comprising the expression vector of claim 23 under conditions whereby the nucleic acid molecule is expressed, thereby producing the antibody or antigen-binding portion; and
isolating the antibody or antigen-binding portion from the host cell or culture.
25. A recombinant host cell comprising the nucleic acid molecule of claim 22 .
26. An anti-C-MET antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO: 34), HCDR2 of MGIINPSGGSTSYAQKFQG (SEQ ID NO: 35) and HCDR3 of QEITTEFDY (SEQ ID NO: 36); and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYAQSYLH (SEQ ID NO: 57), LCDR2 of RGSTRET (SEQ ID NO: 56) and LCDR3 of QQSKESPLT (SEQ ID NO: 47).
27. An anti-C-MET antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO: 34), HCDR2 of MGIINPSGGSTSYAQKFQG (SEQ ID NO: 35) and HCDR3 of QEITTEFDY (SEQ ID NO: 36); and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYANSYLH (SEQ ID NO: 37), LCDR2 of RGSTRET (SEQ ID NO: 56) and LCDR3 of QQSKESPLT (SEQ ID NO: 47).
28. An anti-C-MET antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO: 34), HCDR2 of MGIINPSGGSTSYAQKFQG (SEQ ID NO: 35) and HCDR3 of QEITTEFDY (SEQ ID NO: 36); and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYANSYLH (SEQ ID NO: 37), LCDR2 of RGSTRET (SEQ ID NO: 56) and LCDR3 of QQSKSEPLT (SEQ ID NO: 39).